hAChE/hBACE-1-IN-4

CAS: 229476-71-5 F: C21H24N4O2 W: 364.44

hAChE/hBACE-1-IN-4 (compound AK-2) is a quinazoline derivative. hAChE/hBACE-1-IN-4 shows significant inhibitory activity

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	hAChE/hBACE-1-IN-4 (compound AK-2) is a quinazoline derivative. hAChE/hBACE-1-IN-4 shows significant inhibitory activity against hAChE and hBACE-1 enzymes (hAChE, IC50=0.283 μM; hBACE-1, IC50=0.231 μM). hAChE/hBACE-1-IN-4 has the potential to inhibit Aβ aggregation. hAChE/hBACE-1-IN-4 has non-neurotoxicity , blood-brain barrier permeability and oral activity. hAChE/hBACE-1-IN-4 can be used in Alzheimer's disease research[1].
Invitro	hAChE/hBACE-1-IN-4 (10, 20, 40 和 80 μM; 24 h) 具有非神经毒性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> hAChE/hBACE-1-IN-4 相关抗体: Cell Viability Assay[1] Cell Line:
In Vivo	hAChE/hBACE-1-IN-4 (500 mg/kg，口服， 14 天) 具有很大的安全边际，可以安全地用于进一步的体内研究[1]。hAChE/hBACE-1-IN-4 (500 mg/kg，口服， 9 天) 抑制 BACE-1 活性来恢复认知缺陷，在测试剂量下具有抗 aβ 药物的作用[1]。hAChE/hBACE-1-IN-4 (500 mg/kg，灌胃， 4 天) 具有穿过血脑屏障的能力，达到其在脑组织中的特定作用部位[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	229476-71-5
Formula	C21H24N4O2
Molar Mass	364.44
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Verma A, Waiker D K, Singh N, et al. Lead optimization based design, synthesis, and pharmacological evaluation of quinazoline derivatives as multi-targeting agents for Alzheimer’s disease treatment[J]. European Journal of Medicinal Chemistry, 2024: 116450.

Ras Inhibitory Peptide